Rifamicin is a semisynthetic rifamycin derived from Amycolatopsis mediterranei. It was first marketed in 1966.
It has a useful range of activity allowing it to be used, usually in combination with a wide range of bacterial illness. It is a standard first line therapy for several infections including:
- Staphylococcus aureus
- Buruli ulcer
- Meningococcal chemoprophylaxis
- Haemophilus influenzae chemoprophylaxis
- Legionnaire's disease